Harnessing the Potential of Gene Therapies: Innovations and Improvements in Viral Gene Therapy

Despite the considerable promise that viral gene therapies hold for rare disease patients, the prohibitive cost of development and relatively low commercial interest for rare disease treatments can prevent cutting edge therapies from reaching their full potential. Join experts in viral gene therapy development and manufacturing to learn about innovations and improvements that address key barriers in viral gene therapies.

Guest speaker, Steven Gray, Professor in Pediatric Neurology at the University of Texas Southwestern Medical Center, will discuss the potential of AAV-mediated gene therapy as a platform approach to treat multiple genetic neurological diseases, and provide suggestions to streamline translational studies and reduce costs. In addition, Eric Talley, Senior Technical Sales Specialist at Aldevron, will outline improvements and innovations that are addressing challenges to viral gene therapy manufacturing.

Key learning objectives:

- Viral gene therapy approaches for genetic diseases
- How regulatory pathways and technological innovations can streamline studies and reduce costs
- Manufacturing solutions to address key challenges and support development of these life changing therapies

Register Today

Speakers

Steven J. Gray, Ph.D. Helen J. and Robert S. Strauss Distinguished Professor in Pediatric Neurology University of Texas Southwestern Medical Center Dr. Steven Gray received a B.S. degree with honors from Auburn University followed by a Ph.D. in molecular biology from Vanderbilt University and postdoctoral training at the UNC Chapel Hill Gene Therapy Center. He is currently a Professor in the Department of Pediatrics at the University of Texas Southwestern Medical Center. Dr. Gray is the co-director of the UTSW Gene Therapy Program and director of the UTSW Viral Vector Facility. He maintains affiliations with the Department of Molecular Biology, the Department of Neurology, and the Eugene McDermott Center for Human Growth and Development at UT Southwestern. Dr. Gray’s core expertise is in AAV gene therapy vector engineering, followed by optimizing approaches to deliver a gene to the nervous system. His research focus has also been heavily focused in developing AAV-based treatments for neurological diseases, some of which have translated into clinical trials. He is inventor on over 25 awarded or pending patents and author on over 100 publications related to gene therapy.

Eric Talley Senior Technical Sales Specialist Aldevron Eric Talley is a seasoned expert in the cell and gene therapy industry, currently serving as a Technical Sales Specialist at Aldevron, where he has worked for the past five years. He uses his extensive experience to help clients achieve their scientific and therapeutic goals. Before joining Aldevron, Eric was a GMP Coordinator at Nationwide Children’s Hospital, managing complex viral vector projects for gene therapy applications. He holds an MBA from Franklin University, focusing on business administration and management, and a Bachelor of Applied Science in Medical Biotechnology from the University of Kentucky. Eric's combined expertise in biotechnology and business administration allows him to provide valuable support and insights to his clients, contributing to advancements in the field.